Kallio J P, Hirvikoski P, Helin H, Kellokumpu-Lehtinen P, Luukkaala T, Tammela T L J, Martikainen P M
Department of Urology, Tampere University Hospital, PO Box 2000, FIN-33521 Tampere, Finland.
Br J Cancer. 2003 Oct 6;89(7):1266-9. doi: 10.1038/sj.bjc.6601241.
Epidermal growth factor receptor (EGFR) is a key factor in tumorigenesis. The association between EGFR expression and prognosis in renal cell carcinoma (RCC) is not clear. In our study of 134 RCCs, the cellular location of immunostaining was evaluated and patients with EGFR-positive tumours with prominent membranous staining had a good prognosis. Their overall survival was significantly longer (P=0.004) than that of patients with either EGFR-negative tumours or with mainly cytoplasmic staining. However, further studies on the different EGFR expression patterns in RCC are needed to clarify their role in the progression of the disease.
表皮生长因子受体（EGFR）是肿瘤发生中的一个关键因素。肾细胞癌（RCC）中EGFR表达与预后之间的关联尚不清楚。在我们对134例肾细胞癌的研究中，评估了免疫染色的细胞定位，EGFR阳性肿瘤且有明显膜染色的患者预后良好。他们的总生存期显著长于EGFR阴性肿瘤患者或主要为细胞质染色的患者（P=0.004）。然而，需要对肾细胞癌中不同的EGFR表达模式进行进一步研究，以阐明它们在疾病进展中的作用。
